Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: Comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-A report from the acute leukemia working party of theeuropean group for blood and marrow transplantation

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3549-3556

  Nagler, Arnon ^a   Rocha, Vanderson ^b   Labopin, Myriam ^c   Unal, Ali ^g   Ben Othman, Tarek ^h   Campos, Antonio ⁱ   Volin, Liisa ^j   Poire, Xavier ^k   Aljurf, Mahmoud ^l   Masszi, Tamás ^m   Socie, Gerard ^d   Sengelov, Henrik ⁿ   Michallet, Mauricette ^e   Passweg, Jakob ^o   Veelken, Hendrik ^p   Yakoub Agha, Ibrahim ^f   Shimoni, Avichai ^a   Mohty, Mohamad ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c HÔPITAL SAINT ANTOINE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g Erciyes Medical School   (Turkey)

^h CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

ⁱ PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^m Szent Laszlo Hospital   (Hungary)

ⁿ Rigshospitalet   (Denmark)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIBLING; SURVIVAL RATE; TREND STUDY; TUMOR ENGRAFTMENT; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; REMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84891601014     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.8114     Document Type: Article

References (37)

1. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
2. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
3. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007
4. Fefer A, Einstein AB, Thomas ED, et al: Bonemarrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 290:1389-1393, 1974
5. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382-1388, 1987
6. Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347-1353, 1983
7. Bertz H, Potthoff K, Mertelsmann R, et al: Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: Excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 19:1169-1173, 1997
8. Blaise D, Maraninchi D, Archimbaud E, et al: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen-A report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578-2582, 1992
9. Ringdén O, Ruutu T, Remberger M, et al: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 83:2723-2730, 1994
10. Litzow MR, Pérez WS, Klein JP, et al: Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenousleukaemia in first remission. Br J Haematol 119: 1115-1124, 2002
11. Socié G, Clift RA, Blaise D, et al: Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 98:3569-3574, 2001
12. Ringdén O, Remberger M, Ruutu T, et al: Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia-Nordic Bone Marrow Transplantation Group. Blood 93:2196-2201, 1999
13. Hartman AR, Williams SF, Dillon JJ: Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs. total body irradiation: A meta-analysis. Bone Marrow Transplant 22:439-443, 1998
14. Shi-Xia X, Xian-Hua T, Hai-Qin X, et al: Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: A meta-analysis. Leuk Lymphoma 51:50-60, 2010
15. Ljungman P, Hassan M, Békássy AN, et al: High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20:909-913, 1997
16. Slattery JT, Sanders JE, Buckner CD, et al: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31-42, 1995
17. Dix SP, Wingard JR, Mullins RE, et al: Association of busulfan area under the curve with venoocclusive disease following BMT. Bone Marrow Transplant 17:225-230, 1996
18. Grochow LB, Jones RJ, Brundrett RB, et al: Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55-61, 1989
19. Uberti JP, Agovi MA, Tarima S, Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 46:34-43, 2011
20. Shimoni A, Bielorai B, Toren A, et al: Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. Exp Hematol 31:428-434, 2003
21. Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 20:322-328, 2006
22. Shimoni A, Hardan I, Shem-Tov N, et al: Comparison between two fludarabine-based reducedintensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/ melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 21:2109-2116, 2007
23. Kashyap A, Wingard J, Cagnoni P, et al: Intravenous versus oral busulfan as part of a busulfan/ cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8:493-500, 2002
24. Lee JH, Choi SJ, Lee JH, et al: Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs. oral busulfan in adults conditioned with busulfanα cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84:321-330, 2005
25. Ciurea SO, Andersson BS: Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:523-536, 2009
26. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255-267, 1993
27. Almog S, Kurnik D, Shimoni A, et al: Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant 17:117-123, 2011
28. Andersson BS, Madden T, Tran HT, et al: Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 6:548-554, 2000
29. Andersson BS, de Lima M, Thall PF, et al: Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14:672-684, 2008
30. de Lima M, Couriel D, Thall PF, et al: Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857-864, 2004
31. Alatrash G, de Lima M, Hamerschlak N, et al: Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 17:1490-1496, 2011
32. Andersson BS, de Lima M, Thall PF, et al: Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 21:S11-S15, 2009 (suppl 1)
33. Andersson BS, Kashyap A, Gian V, et al: Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 8:145-154, 2002
34. Sobocinski K, Thall PF, Bekele BN, et al: Matched pairs analysis of IV vs. PO Busulfan as a conditioning agent prior to transplantation. Blood 104, 2004 (suppl 1; abstr 349)
35. Ferrara JL: Pathogenesis of acute graft-versushost disease: Cytokines and cellular effectors. J Hematother Stem Cell Res 9:299-306, 2000
36. Harris AC, Ferrara JL, Braun TM, et al: Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 119:2960-2963, 2012
37. Mohty B, Mohty M: Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J 1:1-4, 2011